Fiscal Year Earnings Estimate on Achillion Pharmaceuticals, Inc.(ACHN)

Achillion Pharmaceuticals, Inc.(ACHN): For the most recent quarter end, Achillion Pharmaceuticals, Inc. reported Annual Earnings of $-0.15. Based on the filings, last years Annual Earnings was, $-0.1. For the most recent quarter end, ACHN reported a surprise Earnings per Share of 6.25% . The consensus estimate for current quarter is $-0.18 and for the current fiscal year, the estimate is $-0.59. For the Next fiscal year, the estimate is $-0.43 based on the consensus.

Achillion Pharmaceuticals, Inc. has received $-0.18 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 6 Financial Advisor in the Stock Trading Firms. Among 6 Analysts, Bottom line EPS Estimate for the current quarter is $-0.19 while the top line estimate is $-0.16 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -245.83%. Achillion Pharmaceuticals, Inc. reported better than expected with a surprise EPS of 6.25% or $0.01 during its most recent quarterly earnings. The Actual EPS was $-0.15 compared to the Estimated EPS of $-0.16.

Achillion Pharmaceuticals Last issued its quarterly earnings results on Aug 4, 2016. The company reported $-0.14 EPS for the quarter, beating the analyst consensus estimate by $ 0.01. Analyst had a consensus of $-0.15.During the same quarter in the previous year, the company posted $-0.25 EPS.

Company has reported several Insider transactions to the SEC, on Dec 23, 2016, Jason S Fisherman (director) purchased 10,000 shares at 3.96 per share price.On Dec 5, 2016, Martha E Manning (EVP, General Counsel) purchased 2,500 shares at 4.09 per share price.On Dec 5, 2016, Joseph Truitt (Chief Commercial Officer) purchased 3,500 shares at 4.06 per share price.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) witnessed a decline in the market cap on Wednesday as its shares dropped 3.45% or 0.15 points. After the session commenced at $4.36, the stock reached the higher end at $4.39 while it hit a low of $4.2. With the volume soaring to 1,131,501 shares, the last trade was called at $4.2. The company has a 52-week high of $10.06. The company has a market cap of $574 million and there are 136,680,890 shares in outstanding. The 52-week low of the share price is $3.78.

ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The companys proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease — HIV, hepatitis and resistant bacterial infections. Achillion sees significant competitive advantages in developing anti-infective drugs compared to developing drugs in other therapeutic areas. The emergence of drug resistance seen with current antiviral and antibacterial therapies creates a continuing need for new drugs, providing a large and growing potential business opportunity. In addition, development cycle times tend to be somewhat shorter in infectious disease than other therapeutic areas, and early drug development results tend to be more predictive of longer term results.


Add Comment